Tenecteplase

DB00031

biotech approved

Deskripsi

Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 1.9 hours (mammalian reticulocytes, in vitro) >20 hours (yeast, in vivo) >10 hours (Escherichia coli, in vivo)
Volume Distribusi -
Klirens (Clearance) * 99 - 119 mL/min [acute myocardial infarction patients]

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Interaksi Obat

704 Data
Apixaban Apixaban may increase the anticoagulant activities of Tenecteplase.
Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Tenecteplase.
Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Tenecteplase.
Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Tenecteplase is combined with Deferasirox.
Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Cholic Acid.
Glycocholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Taurocholic acid.
Obeticholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Hyodeoxycholic Acid.
Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Tenecteplase.
Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Tenecteplase.
Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Tenecteplase is combined with Obinutuzumab.
Rivaroxaban Tenecteplase may increase the anticoagulant activities of Rivaroxaban.
Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Tenecteplase is combined with Sugammadex.
Tibolone Tibolone may increase the anticoagulant activities of Tenecteplase.
Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Tenecteplase.
Urokinase Urokinase may increase the anticoagulant activities of Tenecteplase.
Vitamin E Vitamin E may increase the anticoagulant activities of Tenecteplase.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Tenecteplase.
Aprotinin The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Aprotinin.
Ginkgo biloba Ginkgo biloba may increase the anticoagulant activities of Tenecteplase.
Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Tenecteplase.
Quinine The therapeutic efficacy of Tenecteplase can be increased when used in combination with Quinine.
Quinidine The therapeutic efficacy of Tenecteplase can be increased when used in combination with Quinidine.
Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Tenecteplase.
Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Tenecteplase.
Pentoxifylline The therapeutic efficacy of Tenecteplase can be increased when used in combination with Pentoxifylline.
Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Tenecteplase.
Levocarnitine The therapeutic efficacy of Tenecteplase can be increased when used in combination with Levocarnitine.
Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Tenecteplase.
Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Tenecteplase.
Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Tenecteplase.
Mestranol The risk or severity of adverse effects can be increased when Mestranol is combined with Tenecteplase.
Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Tenecteplase.
Quinestrol Quinestrol may decrease the anticoagulant activities of Tenecteplase.
Hexestrol Hexestrol may decrease the anticoagulant activities of Tenecteplase.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Tenecteplase.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Tenecteplase.
Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Tenecteplase.
Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Tenecteplase.
Zeranol Zeranol may decrease the anticoagulant activities of Tenecteplase.
Equol Equol may decrease the anticoagulant activities of Tenecteplase.
Methallenestril Methallenestril may decrease the anticoagulant activities of Tenecteplase.
Epimestrol Epimestrol may decrease the anticoagulant activities of Tenecteplase.
Moxestrol Moxestrol may decrease the anticoagulant activities of Tenecteplase.
Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Tenecteplase.
Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Tenecteplase.
Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Tenecteplase.
Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Tenecteplase.
Biochanin A Biochanin A may decrease the anticoagulant activities of Tenecteplase.
Formononetin Formononetin may decrease the anticoagulant activities of Tenecteplase.
Estriol Estriol may decrease the anticoagulant activities of Tenecteplase.
Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Tenecteplase.
Mesalazine The risk or severity of bleeding can be increased when Mesalazine is combined with Tenecteplase.
Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Tenecteplase.
Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Tenecteplase.
Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Tenecteplase.
Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Tenecteplase.
Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Tenecteplase.
Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Tenecteplase.
Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Tenecteplase.
Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Tenecteplase.
Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Tenecteplase.
Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Tenecteplase.
Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Tenecteplase.
Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Tenecteplase.
Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Tenecteplase.
Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Tenecteplase.
Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Tenecteplase.
Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Tenecteplase.
Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Tenecteplase.
Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Tenecteplase.
Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Tenecteplase.
Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Tenecteplase.
Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Tenecteplase.
Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Tenecteplase.
Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Tenecteplase.
Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Tenecteplase.
Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Tenecteplase.
Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Tenecteplase.
Olsalazine The risk or severity of bleeding can be increased when Olsalazine is combined with Tenecteplase.
Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Tenecteplase.
Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Tenecteplase.
Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Tenecteplase.
Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Tenecteplase.
Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Tenecteplase.
Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Tenecteplase.
Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Tenecteplase.
Tiaprofenic acid The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Tenecteplase.
Etoricoxib The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Tenecteplase.
Taxifolin The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Tenecteplase.
Oxyphenbutazone The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Tenecteplase.

Target Protein

Plasminogen PLG

Referensi & Sumber

Artikel (PubMed)
  • PMID: 15650539
    Gurbel PA, Hayes K, Bliden KP, Yoho J, Tantry US: The platelet-related effects of tenecteplase versus alteplase versus reteplase. Blood Coagul Fibrinolysis. 2005 Jan;16(1):1-7.
  • PMID: 15744554
    Melzer C, Richter C, Rogalla P, Borges AC, Theres H, Baumann G, Laule M: Tenecteplase for the treatment of massive and submassive pulmonary embolism. J Thromb Thrombolysis. 2004 Aug;18(1):47-50.
  • PMID: 16084152
    Ohman EM, Van de Werf F, Antman EM, Califf RM, de Lemos JA, Gibson CM, Oliverio RL, Harrelson L, McCabe C, DiBattiste P, Braunwald E: Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. Am Heart J. 2005 Jul;150(1):79-88.
  • PMID: 16380055
    De Luca G, Suryapranata H, Chiariello M: Tenecteplase followed by immediate angioplasty is more effective than tenecteplase alone for people with STEMI. Commentary. Evid Based Cardiovasc Med. 2005 Dec;9(4):284-7. Epub 2005 Nov 2.
  • PMID: 16488800
    Authors unspecified: Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006 Feb 18;367(9510):569-78.

Contoh Produk & Brand

Produk: 7 • International brands: 0
Produk
  • Metalyse
    Injection, powder, for solution • 8000 units • Intravenous • EU • Approved
  • Metalyse
    Injection, powder, for solution • 10000 units • Intravenous • EU • Approved
  • Metalyse
    Injection, powder, for solution • 5000 units • Intravenous • EU • Approved
  • TNKase
    Kit • - • Intravenous; Topical • US • Approved
  • TNKase
    Injection, powder, lyophilized, for solution; Kit • 52.5 mg/50mg • Intravenous • US • Approved
  • TNKase
    Powder, for solution • 50 mg / vial • Intravenous • Canada • Approved
  • TNKase
    Injection, powder, lyophilized, for solution; Kit • 52.5 mg/50mg • Intravenous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul